[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"differentiated-thyroid-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:differentiated-thyroid-cancer":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,60,93,118,145,173,196,216,241,265,287,307,327,348,376],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":39,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100480603","phase-1-a-study-to-learn-about-the-study-medicine-called-pf-07799544-as-monotherapy-or-in-combination-in-people-with-advanced-solid-tumors-100480603",false,"NCT05538130","A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors","A PHASE 1A\u002FB OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH BRAF-MUTANT MELANOMA AND OTHER SOLID TUMORS","Phase 1b Inclusion Criteria:\n\n* Diagnosis of advanced\u002Fmetastatic solid tumor (excluding colorectal cancer)\n* Measurable disease by RECIST version 1.1\n* Evidence of a BRAF V600 mutation\n* Prior therapy per tumor cohort\n* Adequate organ function per protocol\n\nPhase 1b Exclusion Criteria:\n\n* Other active malignancy within 3 years\n* Presence of leptomeningeal disease\n* History or current evidence of retinal vein occlusion (RVO) or history of retinal degenerative disease\n* Concurrent neuromuscular disorder associated with elevated creatine kinase (CK)\n* Active gastrointestinal disease as defined per protocol\n* History of interstitial lung disease as defined per protocol","ALL","16 Years",{"count":19,"type":20},124,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two parts: PF-07799544 as a single agent (Phase 1a) and PF-07799544 in combination with another study medicine called PF-07799933 (Phase 1b).\n\nPhase 1a is no longer open for enrollment. In Phase1b (noted as \"this study\"), we are seeking participants who have:\n\n* a solid tumor which is metastatic or recurrent (excluding colorectal cancer)\n* tumor with the mutation (abnormal gene) called \"BRAF V600\"\n* received required prior treatment for cancer per cohort assigned.\n\nAll participants in this study will receive both study medicines. Both study medicines are tablets that are taken by mouth at home twice a day.\n\nParticipants will receive study medicines until their cancer is no longer responding, unacceptable side effects, or 2 years. Participants may continue to receive study therapy beyond 2 years. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and effective.",[26,27,28,29,30,31,32,33,34,35,36,37,38],"Melanoma","Glioma","Thyroid Cancer","Non-Small Cell Lung Cancer","Malignant Neoplasms","Brain Neoplasms","Advanced or Metastatic Solid Tumors","HGG","LGG","Low Grade Glioma","High Grade Glioma","Differentiated Thyroid Cancer","NSCLC (Non-small Cell Lung Cancer)",[40,41,42,43,44,45,46],"solid tumors","BRAF","advanced solid tumors","B-Raf","MAPK","neoplasms","BRAF V600","RECRUITING","2026-06-29",{"date":50,"type":51},"2026-07-01","ACTUAL",{"date":53,"type":51},"2022-11-30",{"date":55,"type":20},"2029-06-18",{"name":57,"class":58},"Pfizer","INDUSTRY",83,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":71,"briefSummary":72,"conditions":73,"keywords":77,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100630276","phase-1-drug-repurposing-in-thyroid-carcinoma-a-feasibility-trial-100630276","NCT07485569","Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial","Network Pharmacology-based Personalized Drug Repurposing in Thyroid Carcinoma: a Pilot Feasibility Trial","REPOTHYROID-II","Inclusion Criteria:\n\n* Patients with locally advanced or metastatic TC (such as ATC, PDTC, and RAI refractory DTC progressive under treatment with multikinase inhibitors) for whom no approved conventional treatments are available.\n* Prior anticancer treatment-related toxicities resolved to Grade ≤1 (CTCAE v5.0).\n* Measurable disease per RECIST 1.1\n* ECOG performance status ≤ 2\n* Negative pregnancy test within 7 days prior to starting the study in women of childbearing potential and adequate use of contraception.\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Inability to obtain a (new) biopsy for molecular profiling\n* Pregnancy or breastfeeding.\n* Other active malignancies requiring therapy.\n* Neutropenia (ANC \\\u003C 1.5 × 10⁹\u002FL).\n* Severe uncontrolled medical conditions (renal, cardiac, liver, respiratory).","18 Years",{"count":70,"type":20},10,[23],"This is a phase Ib trial that studies personalized network pharmacology-based drug repurposing in patients with advanced thyroid cancer who have no other treatment options. The main objective is to study if it is feasible to give patients individualized drug combinations selected based on their tumor genetic profile. The secondary objective is to find out whether these treatments are safe and can help control the growth of the patient tumors or stop them from getting worse.",[74,75,37,76],"Thyroid Cancer Stage IV","Anaplastic Thyroid Cancer","Poorly Differentiated Thyroid Carcinoma",[78,79,80,81],"Drug repurposing","Thyroid cancer","Network pharmacology","Personalized therapy","NOT_YET_RECRUITING","2026-06-17",{"date":85,"type":51},"2026-06-22",{"date":87,"type":20},"2026-06-01",{"date":89,"type":20},"2027-09-01",{"name":91,"class":92},"Radboud University Medical Center","OTHER",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":102,"conditions":103,"keywords":104,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100567668","nomogram-for-predicting-difficult-transoral-and-submental-thyroidectomy-100567668","NCT06671184","Nomogram for Predicting Difficult Transoral and Submental Thyroidectomy","Inclusion Criteria:\n\n* Clinical diagnosis of differentiated thyroid cancer with a maximum diameter not exceeding 4 cm\n* Absence of suspicious lateral lymph nodes or distant metastases\n* Participants with high cosmetic expectations\n* Participants who underwent total thyroidectomy and central lymph node dissection.\n\nExclusion Criteria:\n\n* Participants with fusion or fixation of lymph nodes in the neck\n* Participants with history of neck surgery or radiation\n* Participants with vocal fold fixation by preoperative fibrolaryngoscope\n* Participants with preoperative examination suggestive of extrathyroidal invasion\n* Participants with a significantly restricted neck",{"count":100,"type":20},500,"OBSERVATIONAL","No prior studies have stratified the difficulty of transoral and submental thyroidectomy (TOaST). The investigators aimed to investigate preoperative factors as indicators of difficult TOaSTs and to develop a predictive model accordingly.",[37],[105,106,107],"Differentiated thyroid cancer","Transoral and submental thyroidectomy","Surgical difficulty","2026-05-02",{"date":110,"type":51},"2026-05-07",{"date":112,"type":51},"2021-01-01",{"date":114,"type":20},"2027-12-31",{"name":116,"class":92},"Shanghai 6th People's Hospital",1,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":21,"phases":128,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":117},"100504737","phase-2-pembrolizumab-in-high-risk-thyroid-cancer-100504737","NCT05852223","Pembrolizumab in High-risk Thyroid Cancer","Neoadjuvant Pembrolizumab in High-risk Thyroid Cancers","NePenThe","Inclusion Criteria:\n\n1. Male\u002Ffemale participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of differentiated thyroid carcinoma candidate to surgery not previously treated will be enrolled in this study.\n2. Patients with a risk \\> 20% for persistent\u002Frecurrent disease: primary tumor \\> 4 cm; multifocal papillary microcarcinoma with extra tumor extension (ETE) and known BRAF V600E mutation; clinical N1; gross ETE (macroscopic invasion of perithyroidal soft tissues); extranodal extension; expected incomplete tumour resection.\n3. Poorly differentiated carcinoma; Hurtle cell carcinoma.\n4. Patients with distant metastasis at diagnosis.\n5. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.\n6. Have measurable disease based on RECIST 1.1.\n7. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the date of allocation\u002Frandomization.\n8. Have adequate organ function as defined in the following table (Table 2) Specimens must be collected within 10 days prior to the start of study treatment.\n9. Male participants:\n\n   A male participant must agree to use a contraception as detailed in Appendix 3 of this protocol during the treatment period and for at least 6 months (e.g. 5 terminal half-lives for pembrolizumab) after the last dose of study treatment and refrain from donating sperm during this period.\n10. female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n    1. Not a woman of childbearing potential (WOCBP).\n    2. a WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 4 months after the last dose of study treatment\n\nExclusion Criteria:\n\n1. A WOCBP who has a positive urine pregnancy test within 72 hours prior to randomization. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n2. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).\n3. Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to randomization.\n4. Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.\n5. Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. Administration of killed vaccines is allowed.\n6. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.\n7. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n8. Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer, or other in-situ (eg, breast carcinoma or cervical cancer in situ that have undergone potentially curative therapy are not excluded).\n9. Has known active CNS metastases and\u002For carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention.\n10. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and\u002For any of its excipients.\n11. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.\n12. Has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease\n13. Has an active infection requiring systemic therapy.\n14. History of Human Immunodeficiency Virus (HIV) infection.\n15. History of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.\n16. Has a known history of active TB (Bacillus Tuberculosis).\n17. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n18. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n19. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.\n20. Has had an allogenic tissue\u002Fsolid organ transplant",{"count":127,"type":20},25,[129],"PHASE2","This window of opportunity trial is studying a checkpoint inhibitor agent to treat differentiated thyroid cancer in a neoadjuvant setting. A checkpoint inhibitor is a compound aimed at restoring tumor immunosurveillance. The name of this agent is pembrolizumab.",[37],[133,134,135],"differentiated thyroid carcinoma","neoadjuvant treatment","pembrolizumab","2026-04-15",{"date":138,"type":51},"2026-04-20",{"date":140,"type":51},"2024-12-20",{"date":142,"type":20},"2026-11",{"name":144,"class":92},"Istituti Clinici Scientifici Maugeri SpA",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":21,"phases":157,"briefSummary":158,"conditions":159,"keywords":163,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":172},"100551280","phase-2-selpercatinib-pre-rai-in-patients-with-ret-fusion-thyroid-cancer-raise-100551280","NCT06458036","Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)","Selpercatinib to Enhance RAI Avidity in Children, Adolescents, and Young Adults With Newly Diagnosed Differentiated Thyroid Cancers Harboring RET Fusions","RAISE","Inclusion Criteria:\n\n1. Age 2-25 years, inclusive\n2. Histologic diagnosis of a differentiated thyroid cancer, status post thyroidectomy and adequate local therapy (e.g., lymph node dissection as per standard of care) for metastatic disease in the neck in the opinion of the treating investigator\n3. Anatomically evaluable disease on chest CT (Computed Tomography) meeting one of the following criteria (obtained within 90 days of enrollment):\n\n   A. multiple (\\> 10) noncalcified solid pulmonary nodules visible on CT and\u002For B. enlarging, discrete pulmonary nodules visible on CT of any number consistent with metastatic disease\n4. Identification of an activating RET gene alteration (fusion or mutation). The RET alteration result should be generated from a laboratory with specific certifications (depending on country requirement) that clearly denotes the presence of a RET alteration without known kinase domain resistance mutation\n5. Lansky\u002FKarnofsky performance status \\>50%\n6. Adequate Organ Function\n\n   A. Bone Marrow Function:\n   * Peripheral absolute neutrophil count (ANC) ≥1500\u002FµL\n   * Platelet count ≥ 100,000\u002FµL (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)\n   * Hemoglobin ≥ 9.0 g\u002FdL at baseline (may receive Red Blood Cell transfusions).\n\n   B. Adequate Renal Function: Creatinine clearance or radioisotope Glomerular Filtration Rate (GFR) ≥ 70 mL\u002Fmin\u002F1.73 m2 or a maximum serum creatinine based on age\u002Fgender.\n\n   C. Adequate Liver Function\n   * Bilirubin (sum of conjugated + unconjugated) \\\u003C \u002F = 1.5 x upper limit of normal (ULN) for age. Except participants with a documented history of Gilbert syndrome who must have a total bilirubin level of \\\u003C3.0X ULN\n   * Alanine aminotransferase (ALT) \\\u003C2.5X ULN OR \\\u003C5x ULN if the liver has tumor involvement. For the purpose of this study, the ULN for ALT is 45 U\u002FL.\n   * Serum albumin ≥ 2 g\u002FdL\n7. Patient must have normal serum potassium, calcium, and magnesium levels (may be receiving supplements)\n8. Men with partners of childbearing potential or women of childbearing potential must agree to use a highly effective contraceptive method during treatment with study drug and for 6 months following the last dose of study drug. Selpercatinib could impair fertility in males and females. Advise women not to breastfeed during treatment with selpercatinib and for 1 week following the final dose\n9. Women of childbearing potential must have a negative pregnancy test (serum or urine, consistent with local regulations) documented within 24 hours prior to treatment with study drug and at least monthly while on study treatment\n\nExclusion Criteria:\n\n1. No prior systemic therapy for thyroid cancer, including RET inhibitors. Note: prior 131I is allowed.\n2. Females who are pregnant or breastfeeding are excluded due to the potential risks of selpercatinib and radioactive iodine to the fetus\u002Fneonate.\n3. Concurrent therapy: Patients currently receiving a strong CYP3A4 inducer or inhibitor are not eligible. Strong inducers or inhibitors of CYP3A4 should be avoided 14 days prior to treatment to the end of the study treatment.\n4. Patients with clinically significant active cardiovascular disease, Torsades de pointes, or history of myocardial infarction within 6 months prior to planned start of study treatment or prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) \\>470 msec.\n5. Have clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the drug.\n6. Are taking a concomitant medication that is known to cause QTc prolongation.\n7. Active hemorrhage or at significant risk for hemorrhage.\n8. Uncontrolled hypertension (blood pressure greater than 140\u002F90 in adults or greater than the 95% for height and gender in children). Use of anti-hypertensives to control blood pressure is permitted.","2 Years","25 Years",{"count":156,"type":20},13,[129],"Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.",[37,160,161,162],"Pediatric Cancer","Cancer","Cancer, Thyroid",[28],"2026-04-13",{"date":136,"type":51},{"date":167,"type":51},"2024-07-29",{"date":169,"type":20},"2031-11-01",{"name":171,"class":92},"Children's Hospital of Philadelphia",4,{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":21,"phases":182,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":195},"100485737","hemithyroidectomy-or-total-thyroidectomy-in-low-risk-thyroid-cancers-100485737","NCT05604963","Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers","HoT","Group 1 (HT already performed prior to diagnosis)\n\nInclusion criteria\n\n• Aged 16 or over\n\nPapillary thyroid cancer:\n\n* pT1b-2 (≤4cm) irrespective of molecular genetic markers\n* R0 resection (clinically excised but microscopic R1 resected tumours at discretion of the local MDT)\n* cN0 or pN0, pNX \\& pN1a (≤5 foci, no extranodal spread)\n* Confined to thyroid or minimal extrathyroidal extension\n* No higher risk histological variants on morphology (small foci allowed at the discretion of the local MDT)\n* No angioinvasion NB. PTC is still eligible where microscopic invasion of endothelial lined small capillary vascular spaces and lymphatic channels are present. It becomes ineligible in the rare instances when there is definite invasion of a larger vascular structure such as a vein with smooth muscle in its wall.\n* Encapsulated FVPTC with capsular invasion only\n* Micro-PTC (≤1cm)\n\n  * multifocal\n  * unifocal with pN1a (≤5 foci; no extranodal spread)\n\nFollicular thyroid cancer (FTC), including oncocytic or Hürthle cell carcinoma:\n\n* pT1b-2 (≤4cm) irrespective of molecular genetic markers\n\n  \\- Minimally invasive, with capsular invasion +\u002F- minimal (≤4 foci) vascular invasion (the latter is now called encapsulated angioinvasive and is at the discretion of the MDT)\n* Confined to thyroid or minimal extrathyroidal extension\n\nExclusion criteria\n\n* \\>4cm\n* unifocal pT1a (≤1cm) PTC or FTC (unless pN1a as above)\n* NIFTP (non-invasive follicular thyroid neoplasm with papillary-like nuclear features)\n* Anaplastic, poorly differentiated or medullary thyroid carcinoma\n* R2\n* gross extrathyroidal extension\n* pT4 or macroscopic tumour invasion of loco-regional tissues or structures\n* pN1a with \\>5 foci or extranodal spread\n* pN1b\n* M1\n* Aggressive PTC with any of the following features:\n\n  * Widely invasive\n  * Poorly differentiated\n  * Anaplastic\n  * predominance of Tall cell, Columnar cell, Hobnail, Diffuse sclerosing and other higher risk variants\n* FTC, including oncocytic or Hürthle cell cancer with any of the following features:\n\n  * Minimally invasive with extensive vascular invasion (now called encapsulated angioinvasive) (\\>4 foci)\n  * Widely invasive\n  * Poorly differentiated\n  * Anaplastic\n\nGroup 2 (DTC on cytology or after core biopsy, who has not had prior thyroid surgery yet)\n\nInclusion criteria\n\n* Aged 16 or over\n* 'low risk' differentiated thyroid cancer confirmed by cytology or core biopsy.\n* cT1b-2 irrespective of molecular genetic markers\n* cN0\n* Contralateral lobe without suspicious nodule(s) (U2, or U3\u002FU4 with Thy2 on FNAC)\n\nExclusion criteria\n\n• M1",{"count":181,"type":20},456,[183],"NA","This is a multi-centre, randomised, non-inferiority, phase III study in patients with low risk differentiated thyroid cancer.\n\nPatients will be identified via oncology multidisciplinary team meetings. There will be two sources of patients in the trial, with the same histological diagnoses and prognosis (i.e. recurrence risk):\n\n* Group 1: Patients who have already had a HT for thyroid problems and are then subsequently diagnosed with low risk DTC will be randomised 1:1 to undergo surveillance only OR a second operation to remove the rest of their thyroid gland (two-stage total thyroidectomy).\n* Group 2: Patients diagnosed with low risk DTC using cytology (Thy5) but no surgery performed will be randomised 1:1 to have either a hemi-thyroidectomy OR a single-stage total thyroidectomy.\n\nThe overall aim of the trial is to determine whether hemithyroidectomy is an acceptable and cost-effective surgical procedure compared to total thyroidectomy in low risk thyroid cancer. Overall, 456 patients will be recruited to the trial. Patients will be initially be followed up post-surgery then 12 monthly for 6 years.",[37],"2026-03-03",{"date":188,"type":51},"2026-03-05",{"date":190,"type":51},"2022-02-14",{"date":192,"type":20},"2031-07-31",{"name":194,"class":92},"University College, London",33,{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":21,"phases":205,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":4},"100627791","phase-1-empirical-radioactive-iodine-therapy-in-dtc-100627791","NCT07453225","Empirical Radioactive Iodine Therapy in DTC","Efficacy of Empirical Radioactive Iodine Therapy in Differentiated Thyroid Carcinoma Patients With Thyroglobulin Elevation Negative Iodine Scintigraphy (TENIS) Syndrome","Inclusion Criteria:\n\n* This study will include adult patients with pathologically proved DTC who underwent total thyroidectomy and received RAI therapy presented to our nuclear medicine unit with evidence of persistent or recurrent biochemical disease during follow up.\n\nExclusion Criteria:\n\n* Undifferentiated thyroid cancer.\n* Patients with evidence of structural disease.\n* Patients less than 18 years old.",{"count":204,"type":20},100,[23,129],"The aim of the study is assessment the efficacy of empiric RAI therapy in DTC patients with elevated thyroglobulin levels and negative iodine scintigraphy.",[37],"2026-02-27",{"date":188,"type":51},{"date":211,"type":20},"2026-04-01",{"date":213,"type":20},"2028-07-01",{"name":215,"class":92},"Assiut University",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":21,"phases":225,"briefSummary":226,"conditions":227,"keywords":228,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":240},"100626501","f-18-tetrafluoroborate-petct-in-differentiated-thyroid-cancer-100626501","NCT07436455","F-18 Tetrafluoroborate PET\u002FCT in Differentiated Thyroid Cancer","NISDETECT","Inclusion Criteria:\n\n* Having undergone surgery for differentiated thyroid cancer and received radioactive iodine therapy\n* Being evaluated for lesion detection due to elevated serum Tg and\u002For ATg levels during post-treatment follow-up\n* Negative or equivocal I-131 whole-body scan findings\n* Karnofsky Performance Status ≥ 50 (or equivalent Eastern Cooperative Oncology Group \\[ECOG\\]\u002FWorld Health Organization \\[WHO\\] performance status)\n* Giving written informed consent\n\nExclusion Criteria:\n\n* Age under 18 years\n* Pregnancy or breastfeeding\n* Failure to provide written informed consent",{"count":224,"type":20},50,[183],"In patients who have undergone surgery for differentiated thyroid cancer and who demonstrate elevated serum Tg and\u002For ATg levels during follow-up after radioactive iodine therapy, lesion detection is performed using neck ultrasonography, thorax CT, and F-18 FDG PET\u002FCT. Diagnostic whole-body scanning with low-dose I-131 is not routinely recommended in follow-up due to its low sensitivity and specificity.\n\nF-18 TFB is a highly specific imaging agent for differentiated thyroid cancer, entering thyroid follicular epithelial cells via the sodium-iodide symporter (NIS), which is expressed on the cell surface and functions through a mechanism similar to that of I-131. As a PET radiotracer, F-18 TFB has been shown to be superior to I-131 in previous studies.\n\nThe primary aim of this study is to comparatively evaluate the role of F-18 TFB PET\u002FCT versus the standard imaging modality F-18 Fluorodeoxyglucose (FDG) PET\u002FCT in lesion detection in patients with differentiated thyroid cancer who demonstrate elevated serum Tg and\u002For ATg levels during follow-up after radioactive iodine therapy.\n\nThe secondary aims are to investigate the factors predicting F-18 TFB PET\u002FCT positivity and to assess the relationship between the semi-quantitative and quantitative parameters derived from F-18 TFB PET\u002FCT and serum thyroglobulin (Tg) and anti-thyroglobulin (ATg) levels.",[28,37],[229,230,231],"F-18-tetrafluoroborate","PET\u002FCT","NIS","2026-02-21",{"date":208,"type":51},{"date":235,"type":51},"2025-11-01",{"date":237,"type":20},"2026-10-01",{"name":239,"class":92},"Ankara University",2,{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":240},"100565855","thyroid-hormone-replacement-after-radio-iodine-value-and-efficacy-100565855","NCT06647602","Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy","THRIVE","Inclusion Criteria:\n\n* Histologically confirmed DTC (papillary thyroid carcinoma, follicular thyroid carcinoma, oncocytic thyroid carcinoma)\n* Classified as high-risk DTC according to the ATA guidelines or, patients for whom the risk of a recurrence is estimated to be higher based on clinical features (assessed by their treating physician).\n* Prepared for RAI-therapy with TH-withdrawal\n* Patients must be fit to adhere to the study protocol\n* Patients must be able to read and understand the Dutch language\n\nExclusion Criteria:\n\n* Pregnancy\n* Patients with comorbidities, such as severe heart failure, (poorly controlled) atrial fibrillation, of which the treating physician decides that L-T3 is unsuitable.\n* Conditions or drugs interfering with thyroid hormone uptake:\n* Patients with a history of atrophic gastritis\n* Patients using proton-pomp inhibitors","75 Years",{"count":250,"type":20},40,"This study will be a multicentre prospective cohort study on TH-substitution after thyroid hormone withdrawal preceding radioiodine treatment.",[37,28,253,254,255],"Levothyroxine","Liothyronine","Thyroid Hormones","2026-02-05",{"date":258,"type":51},"2026-02-10",{"date":260,"type":20},"2026-09-01",{"date":262,"type":20},"2028-12-31",{"name":264,"class":92},"University Medical Center Groningen",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":248,"enrollmentInfo":273,"targetDuration":4,"studyType":21,"phases":274,"briefSummary":275,"conditions":276,"keywords":277,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":117},"100485289","iodine-uptake-after-a-low-iodine-diet-100485289","NCT05599139","Iodine Uptake After a Low Iodine Diet","The Uptake of Radioactive Iodine Before and After a Low Iodine Diet in Patients With Differentiated Thyroid Carcinoma","IULID","Inclusion Criteria:\n\n* Patients, men and women above the age of 18 years, have to be diagnosed with DTC and have to follow a LID prior to the 131I ablation therapy according to the Dutch DTC guideline\n* Patients have to be fit to adhere to the study protocol\n* Patients have to be able to read and understand the Dutch language\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Patients using amiodarone\n* Patients receiving iodinated contrast \\\u003C 3 months before the LID\n* Pregnancy\n* Patients prepared for ablation therapy with rhTSH\n* Renal impairment, EGFR \\\u003C30ml\u002Fmin\u002F1,73m2",{"count":127,"type":20},[183],"The goal of this clinical trial is to compare the difference in thyroid uptake of a low dose radioactive iodine (10 MBq 123-I or 37 MBq 123-I) in athyreotic patients with differentiated thyroid carcinoma before and after a low iodine diet (LID) of 7 days.\n\nThe main question it aims to answer is:\n\n• What is the difference in iodine uptake before and after a LID of 7 days?\n\nUptake of a low dose of 123-iodine will be measured in participants before and after a low iodine diet of 7 days. Researchers will compare the uptake (%) before and after the LID.",[37],[278,279],"Low iodine diet","Iodine uptake",{"date":281,"type":51},"2026-02-06",{"date":283,"type":51},"2023-02-22",{"date":285,"type":20},"2026-08-31",{"name":264,"class":92},{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":16,"minAge":153,"maxAge":294,"enrollmentInfo":295,"targetDuration":4,"studyType":21,"phases":296,"briefSummary":158,"conditions":297,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":306},"100499443","phase-2-larotrectinib-to-enhance-rai-avidity-in-differentiated-thyroid-cancer-100499443","NCT05783323","Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer","Larotrectinib to Enhance RAI Avidity in Patients With Differentiated Thyroid Cancer Harboring NTRK Fusions (LANTERN)","Inclusion Criteria:\n\n1. Age ≥ 1 year\n2. Histologic diagnosis of a differentiated thyroid cancer, s\u002Fp thyroidectomy and adequate local therapy (e.g., lymph node dissection as per standard of care) for metastatic disease in the neck in the opinion of the treating investigator\n3. Anatomically evaluable disease on chest CT meeting one of the following criteria (obtained within 90 days of enrollment):\n\n   A. multiple (\\> 10) noncalcified solid pulmonary nodules visible on CT and\u002For B. enlarging, discrete pulmonary nodules visible on CT of any number consistent with metastatic disease\n4. Identification of an neurotrophic tyrosine receptor kinase (NTRK) (NTRK1, NTRK2, or NTRK3) gene fusion in a CLIA\u002FCAP accredited laboratory without known kinase domain resistance mutation\n5. Lansky\u002FKarnofsky performance status ≥ 50%\n6. Adequate Organ Function\n\n   A. Bone Marrow Function:\n   * Peripheral absolute neutrophil count (ANC) ≥ 1000\u002Fmm3\n   * Platelet count ≥ 100,000\u002Fmm3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)\n   * Hemoglobin ≥ to 8.0 g\u002FdL at baseline (may receive red blood cell (RBC) transfusions).\n\n   B. Adequate Renal Function:\n\n   Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 70 mL\u002Fmin\u002F1.73 m2 or a maximum serum creatinine based on age\u002Fgender as follows:\n\n   Age Maximum Serum Creatinine (mg\u002FdL) Male Female 1 to \\\u003C 2 years 0.6 0.6 2 to \\\u003C 6 years 0.8 0.8 6 to \\\u003C 10 years 1 1 10 to \\\u003C 13 years 1.2 1.2 13 to \\\u003C 16 years 1.5 1.5\n\n   ≥ 16 years 1.7 1.7\n\n   C. Adequate Liver Function\n   * Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x upper limit of normal (ULN) for age.\n   * Serum glutamic-pyruvic transaminase (SGPT) (ALT) ≤ 135 U\u002FL. For the purpose of this study, the ULN for SGPT is 45 U\u002FL.\n   * Serum albumin ≥ 2 g\u002FdL\n7. Female patients of reproductive potential must agree to use a highly effective contraceptive method for the duration of study therapy and for at least one month after the final dose of larotrectinib. Males of reproductive potential with a non-pregnant female partner of child-bearing potential must use a highly effective contraception for the duration of the study and for at least one month after the final dose of larotrectinib.\n\nExclusion Criteria\n\n1. No prior systemic therapy for thyroid cancer, including tropomyosin receptor kinase (TRK) inhibitors. Note that prior 131I is permitted.\n2. Females who are pregnant or breastfeeding are excluded due to the potential risks of larotrectinib and RAI to the fetus\u002Fneonate.\n3. Concurrent therapy: Patients currently receiving a strong CYP3A4 inducer or inhibitor are not eligible. Strong inducers or inhibitors of CYP3A4 should be avoided 14 days prior to treatment to the end of the study treatment.","99 Years",{"count":156,"type":20},[129],[37,160,161,162],"2025-11-12",{"date":300,"type":51},"2025-11-14",{"date":302,"type":51},"2024-02-14",{"date":304,"type":20},"2027-10-01",{"name":171,"class":92},5,{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":16,"minAge":314,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":317,"conditions":318,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":320,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":326},"100441176","targeted-therapy-to-increase-rai-uptake-in-metastatic-dtc-100441176","NCT05024929","Targeted Therapy to Increase RAI Uptake in Metastatic DTC","Targeted Therapy to Increase RAI Uptake in Patients With Metastatic Differentiated Thyroid Cancer","Inclusion Criteria (Prospective Cohort):\n\n1. Patients with a histologic diagnosis of differentiated thyroid cancer\n2. Presence of an neurotrophic tyrosine kinase receptors (NTRK)-fusion, RET-fusion, anaplastic lymphoma kinase (ALK)-fusion, BRAF V600 mutation, BRAF-fusion or other targetable alteration identified in a Clinical Laboratory Improvement Amendments\u002FCollege of American Pathologists (CLIA\u002FCAP) laboratory\n3. Anatomically evaluable disease on chest Computed tomography (CT) meeting oneo f the following criteria (obtained within 180 days of enrollment):\n\n   1. multiple (10 or more) noncalcified solid pulmonary nodules visible on CT and\u002For\n   2. enlarging, discrete pulmonary nodules visible on CT of any number consistent with metastatic disease\n4. Patients for whom systemic therapy with an oncogene-specific kinase inhibitor is planned from commercial supply or as part of a separate therapeutic clinical trial (that does not include data sharing with this protocol)\u002Fcompassionate access protocol\u002Fsingle patient investigational new drug (IND). Such agents include, but are not limited to:\n\n   1. Larotrectinib, entrectinib, selitrectinib, and repotrectinib for NTRK fusions\n   2. Selpercatinib and pralsetinib for RET fusions\n   3. Crizotinib, lorlatinib, repotrectinib, and alectinib for ALK fusions\n   4. Dabrafenib and\u002For trametinib for BRAF V600 mutations\n   5. Oncogene-specific kinase inhibitors other than those specifically delineated above must be approved by the overall study PI prior to enrollment\n\nInclusion Criteria (Data Sharing Cohort):\n\n1\\. Patients enrolled on other oncogene-specific targeted therapy trials who undergo whole body thyroid scan approximately 28 days after beginning targeted therapy and agree to data sharing as part of the consent process for that trial.\n\nExclusion Criteria (All Cohorts):\n\n1. No prior oncogene-specific targeted therapy allowed. However, patients may enroll within 4 weeks of starting oncogene-specific therapy if a pre-therapy WBS is available. Prior therapy with non-oncogene specific multi-thyrosine kinase inhibitors (such as sorafenib, lenvatinib, and\u002For cabozantanib) is allowed.\n2. Females who are pregnant or breastfeeding are excluded due to the potential risks of the RAI used in the WBS to the fetus\u002Fneonate.\n3. Patients who require sedation\u002Fgeneral anesthesia to complete a WBS are excluded.\n4. U.S. Military Personnel are excluded due to the Children's Hospital of Philadelphia (CHOP) Institutional Review Board (IRB) requirements.","0 Years",{"count":316,"type":20},32,"Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become available. While Investigators know that these drugs shrink DTC tumors in many cases, the impact on radioactive iodine (RAI) avidity has not been systematically studied.",[319,160,37],"Papillary Thyroid Cancer",{"date":300,"type":51},{"date":322,"type":51},"2021-07-16",{"date":324,"type":20},"2033-02-01",{"name":171,"class":92},9,{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":117},"100499931","gender-based-impact-on-safety-and-efficacy-of-lenvatinib-in-patients-with-differentiated-thyroid-cancer-100499931","NCT05789667","Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer","Observational Study on Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer","Gisel","Inclusion Criteria:\n\n* Patients with refractory iodine DTC treated with lenvatinib\n* Signed written informed consent\n\nExclusion Criteria:\n\n\\- Age \\\u003C 18 years",{"count":224,"type":20},"Lenvatinib is approved for the treatment of radioiodine refractory differentiated thyroid cancer. Despite gender can play a crucial role un in safety and efficacy of oncological product, little is know on gender difference in lenvatinb effacacy and safety in the context of radioiodine refractory differentiated thyroid cancer.\n\nThe primary objective of the study is to assess safety and toxicity profile in male and female patients in terms of dose reduction. The secondary objectives are to assess sex and gender difference in: the number and the incidence of adverse events; response rate according to RECIST criteria 1.1; progression free survival, overall survival and duration of response.",[37,338],"Gender","2024-12-05",{"date":341,"type":51},"2024-12-06",{"date":343,"type":51},"2020-05-27",{"date":345,"type":20},"2025-12-31",{"name":347,"class":92},"Regina Elena Cancer Institute",{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":21,"phases":358,"briefSummary":359,"conditions":360,"keywords":361,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":375},"100534160","phase-2-sacituzumab-govitecan-in-thyroid-cancers-100534160","NCT06235216","Sacituzumab govitEcan in THYroid Cancers","A Multicenter, Open Label, Two Cohort, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of the Anti-TROP2 Antibody-drug Conjugate Sacituzumab Govitecan in Patients With Advanced Differentiated and Anaplastic Thyroid Neoplasms.","SETHY","Inclusion Criteria:\n\n1. Institutional Review Board (IRB)\u002FIndependent Ethics Committee (IEC) approved written informed consent.\n2. Patient is ≥ 18 years of age.\n3. Patient has histologically confirmed metastatic or locally advanced unresectable radioactive-iodine refractory differentiated thyroid cancer (cohort A) or anaplastic thyroid carcinoma (cohort B).\n4. Prior therapy in each cohort:\n\n   1. Cohort A: Patients must have experienced progression on at least one previous treatment line with approved systemic therapies (Sorafenib, Lenvatinib or Cabozantinib) and a maximum of 3 prior systemic therapies.\n   2. Cohort B: Patients should be included in first-line setting or after failure of any systemic therapy (up to 1 prior treatment lines).\n5. Patient has radiographically documented and measurable metastatic or locally advanced disease at baseline.\n6. An archival tumor tissue sample should be available for submission to the central laboratory for translational studies. If an archival tumor tissue sample is not available, a new biopsy tissue sample should be provided. No central pathological review will be needed to include the patient in the trial.\n7. Patient has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n8. The following baseline laboratory data without transfusional support:\n\n   1. Neutrophil count (ANC) ≥ 1,500\u002Fmm3.\n   2. Platelet count ≥ 100 × 109\u002FL.\n   3. Hemoglobin ≥ 9 g\u002FdL.\n   4. Serum bilirubin ≤ 1.5 × upper limit of normal (ULN). Note: patients with Gilbert's disease are excluded.\n   5. Serum albumin \\> 3 g\u002FdL.\n   6. Creatinine clearance (CrCl) ≥ 60 mL\u002Fmin as estimated by the Cockroft-Gault formula or as measured by 24 hour urine collection (GFR can also be used instead of CrCl).\n   7. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN or ≤ 5 xULN for patients with liver metastases.\n9. Female patients must either:\n\n   1. Be of nonchildbearing potential:\n\n      I)Postmenopausal \\*(defined as at least 1 year without any menses) prior to screening , or II) Documented surgically sterile (e.g.hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or bilateral tubal occlusion).\n\n      \\*Those who are amenorrheic due to an alternative medical cause are not considered postmenopausal and must follow the criteria for childbearing potential subjects.\n\n      OR\n   2. If of childbearing potential:\n\n   I) Agree not to try to become pregnant during the study and for at least 6 months after the final study drug administration, II) And have a negative urine or serum pregnancy test within 7 days prior to Day 1 (females with false positive results and documented verification of negative pregnancy status are eligible for participation), III) And if heterosexually active, agree to abstinence (if in line with the usual preferred lifestyle of the patient) or consistently use a condom plus 1 form of highly effective birth control per locally accepted standards starting at screening and throughout the study period and for at least 6 months after the final study drug administration.\n10. Female patients must agree not to breastfeed or donate ovules starting at screening and throughout the study period, and for at least 6 months after the final study drug administration.\n11. Male patients must not donate sperm starting at screening and throughout the study period, and for at least 6 months after the final study drug administration.\n12. Male patients with a partner with childbearing potential, or who is pregnant or breastfeeding must agree to abstinence or use a condom plus 1 form of highly effective birth control throughout the study period and for at least 6 months after the final study drug administration.\n13. Patient agrees not to participate in another interventional study while on treatment in the present study.\n\nExclusion Criteria:\n\n1. Patient has central nervous system (CNS) metastases.\n2. Patient has ongoing clinically significant toxicity (Grade 2 or higher with the exception of alopecia) associated with prior treatment (including systemic therapy, radiotherapy or surgery).\n\n   Note: if patients received major surgery, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting therapy.\n3. Patient has a history of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy.\n\n   Note: Patients with non melanoma skin cancer, curatively treated localized prostate cancer, or carcinoma in situ of any type (if complete resection was performed) are allowed.\n4. Patient has known active Hepatitis B or active hepatitis C:\n\n   1. Patients who test positive for hepatitis B surface antigen (HBsAg). Patients who test positive for hepatitis B core antibody (anti-HBc) will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease.\n   2. Patients who test positive for HCV antibody. Patients who test positive for HCV antibody will require HCV RNA by quantitative PCR for confirmation of active disease. Patients with a known history of HCV or a positive HCV antibody test will not require a HCV antibody at screening and will only require HCV RNA by quantitative PCR for confirmation of active disease.\n   3. Patients who test positive for HIV antibody.\n5. Patient has a known history of human immunodeficiency virus (HIV) infection (HIV 1 or 2) with detectable viral load OR taking medications that may interfere with SN-38 metabolism.\n6. Patient has documented history of a cerebral vascular event (stroke or transient ischemic attack), or the following criteria for cardiac disease:\n\n   1. Myocardial infarction or unstable angina pectoris within 6 months of enrollment.\n   2. History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of QT interval prolongation.\n   3. New York Heart Association (NYHA) class III or greater congestive heart failure or left ventricular ejection fraction of \\\u003C 40%.\n7. Known history of clinically significant active COPD, or other moderate-to-severe chronic respiratory illness present within 6 months prior to the first dose of study drug.\n8. Patients with active chronic inflammatory bowel disease (ulcerative colitis, Crohn disease) and patients with a history of gastrointestinal obstruction or perforation within 6 months of enrollment.\n9. Patient has uncontrolled hypertension or diabetes.\n10. Patient has radiotherapy or major surgery within 4 weeks prior to the first dose of study drug.\n11. Patients has received a live vaccine within 30 days, or antibiotics within one week prior to the first dose of study drug.\n12. Patient has had chemotherapy, biologics, investigational agents, and\u002For antitumor treatment with immunotherapy that is not completed 2 weeks prior to the first dose of study drug.\n\n    Note: Patients participating in observational studies are eligible.\n13. Patient has previously received topoisomerase 1 inhibitors.\n14. Patient has known hypersensitivity to sacituzumab govitecan or to any excipient contained in the drug formulation.\n15. Patient has other underlying medical conditions that, in the opinion of the investigator, would impair the ability of the patient to receive or tolerate the planned treatment and follow-up.",{"count":357,"type":20},42,[129],"SETHY is a prospective, multicohort, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory differentiated thyroid carcinoma (DTC) or anaplastic thyroid carcinoma (ATC).\n\nThe main hypothesis is that treatment with sacituzumab govitecan, a anti-Trophoblast cell surface antigen 2 (TROP-2), could be an effective treatment option for patients with either differentiated and anaplastic thyroid neoplasms because TROP-2 is highly expressed at the membrane of DTC and ATC.",[37,75],[362,363,364,365],"TROP-2","sacituzumab govitecan","Antibody-drug conjugate","SN-38","2024-10-31",{"date":368,"type":51},"2024-11-01",{"date":370,"type":51},"2024-09-13",{"date":372,"type":20},"2027-12",{"name":374,"class":92},"Grupo Espanol de Tumores Neuroendocrinos",11,{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":248,"enrollmentInfo":383,"targetDuration":4,"studyType":21,"phases":384,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":117},"100515278","phase-2-surufatinib-as-neoadjuvant-treatment-for-locally-advanced-or-metastatic-differentiated-thyroid-cancer-100515278","NCT05989425","Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer","Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer: an Open-label, Multicenter, Single-arm Study","Inclusion Criteria:\n\n* Locally advanced or metastatic thyroid cancer confirmed by histology or cytology, including papillary thyroid carcinoma, follicular thyroid carcinoma, poorly differentiated thyroid cancer, particularly differentiated thyroid cancer. Locally advanced stage refers to: 1) Primary tumor with invasion or adhesion of organs and structures, such as recurrent laryngeal nerve, esophagus, trachea, larynx, encirclement of neck large vessels, mediastinal vessels, extensive invasion of skin, subcutaneous soft tissue or neck muscles; 2). AJCC T4 Stage; 3). Difficult to achieve R0\u002FR1 resection during preoperative assessment;\n* Age 14-75 years;\n* At least one measurable lesion (RECIST 1.1);\n* Eastern Cooperative Oncology Group (ECOG) score 0-1;\n* Expected survival time ≥ 12 weeks;\n* The main organ functions meet the following criteria: Absolute neutrophil value (ANC) ≥ 1.5 × 109 \u002F L; Platelet (PLT) ≥80 × 109 \u002F L; Hemoglobin (HB) ≥9g \u002F dL; White blood cell count\\> 1.5 × 109 \u002F L; Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal value (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 ULN, if with liver metastases, ALT and AST ≤ 5 ULN; Serum creatinine (Cr) ≤ 1.5 ULN or creatinine clearance (CCr) ≥ 50ml \u002F min;\n* Subjects of potential fertility are required to use at least one medically approved contraceptive method (such as an intrauterine device, contraceptive pill, or condom) during the study treatment and for 180 days after the end of the study treatment; The serum HCG test must be negative before the first medication.\n\nExclusion Criteria:\n\n* Prior treatment with anti-angiogenic small molecule targeted drugs;\n* Received other anti-tumor therapy (including but not limited to chemotherapy, radiotherapy, etc.) within 4 weeks prior to treatment, except for TSH suppression treatment;\n* Allergy to the study drug ;\n* Have a history of serious cardiovascular and cerebrovascular diseases;\n* Patients whose imaging showed that the tumor had invaded the important blood vessels or the researchers judged that the tumor was likely to invade important blood vessels during the subsequent study period and caused fatal bleeding;\n* Patients with hypertension that cannot be well controlled by antihypertensive medication (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg);\n* The patient has had other malignant tumors within 5 years (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);\n* The investigator considered that the subject was not suitable to participate in the study due to any clinical or laboratory abnormalities or other reasons.",{"count":316,"type":20},[129],"Locally advanced thyroid cancer has a wide range of surgery, large trauma and high local recurrence rate. It is one of the main causes of death in patients with thyroid cancer. Therefore, more effective treatments are urgently needed. This study is designed to evaluate the efficacy and safety of the Surufatinib for Locally Advanced Thyroid Cancer.",[37],"2023-08-09",{"date":389,"type":51},"2023-08-14",{"date":391,"type":20},"2023-08-04",{"date":393,"type":20},"2026-08-04",{"name":395,"class":92},"Fudan University"]